Lacripep

Dempsey brings worldwide Ophthalmology leadership experience in driving successful drug developmentCHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Robert Dempsey has been appointed to the Company’s Board of Directors. “Robert is a proven industry leader with extensive and highly relevant experience in Ophthalmology and DED,” said Anil Asrani, President and CEO of TearSolutions. “I am genuinely excited and honored to have Robert join our board, as we work together to bring next generation therapeutics to patients suffering from the maladies associated with ocular surface disease.” “I’m thrilled to work closely with the TearSoultions team to help advance their programs and take the Company to the next level,” said Robert Dempsey. “With their lead product’s highly differentiated and well-characterized mechanism of action, human clinical data illustrating speed of relief, safety, and a best-in-class tolerability profile, as well as the potential to work in a majority of patients, I believe we have a novel disease-modifying solution that can bring much needed relief to patients as well as their treating physicians.” Robert brings more than two decades of domestic and global leadership experience in the Ophthalmology space driving successful drug development in public and private sectors through efficient organizational structure and capital investments. His widespread experience in Ophthalmology stems from diverse leadership roles across commercial, business development, medical affairs, and venture-backed startups. Currently, Robert serves as the Chief Executive Officer at AsclepiX Therapeutics focused on advancing an integrin regulating peptide for posterior segment diseases. He joined Asclepix in 2019 after serving as the Chief Executive Officer for TearClear where he accelerated the business and commercial strategies including a successful Series B financing and positive FDA engagements. Prior to that, he served as the Global Head of Ophthalmology at Shire, then Takeda, responsible for one of the top ten largest biopharma M&A deals in 2019, the divestiture of Xiidra® (lifitegrast ophthalmic solution) 5%, to Novartis in June 2019 for up to $5.3B. About TearSolutions, Inc. TearSolutions is a privately held biotechnology company focused on the discovery, development and commercialization of novel therapies for the treatment of patients with Ocular Surface Disease (OSD). The Company is based in Charlottesville, VA and is currently developing bioactive proprietary peptide proteoforms of lacritin, for chronic treatment of the signs and symptoms of dry eye disease (DED) associated with OSD. More information is available at www.tearsolutions.com. About Lacripep™Lacripep was patented by Dr. Gordon Laurie, a professor of Ophthalmology and Cell Biology at the University of Virginia, based on his groundbreaking NIH funded research into the composition of human tears, which led to the discovery of lacritin. Lacritin and Lacripep represent a unique treatment modality that optimizes all three layers of the tear film while restoring corneal health and homeostasis. The intellectual property is exclusively licensed to TearSolutions, Inc. from the University of Virginia Licensing and Ventures Group. Corporate Contact: Anil Asrani, CEO aasrani@tearsolutions.com Source: TearSolutions, Inc.

Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO--(BUSINESS WIRE)-- Axim Biotech, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the receipt of notification by the United States Patent & Trademark Office of several patent allowances. AXIM has been developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including, for example, SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9. This innovative platform allows clinicians to detect with greater speed and accuracy different conditions that, e.g., allow for point of care testing of viruses, diseases, and conditions such as Dry Eye Disease. The platform capability can also be applied to rapid testing for vaccine candidates, including COVID vaccines and a potential Fentanyl vaccine. AXIM’s proprietary platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L. The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment. The allowance confirms that AXIM was a pioneer in developing a rapid point of care Nab test and its novelty. Additionally, the company was notified by the USPTO of a second patent allowance for systems and methods for rapid diagnostic for various cancers. The invention relates to the discovery by AXIM scientists of a unique biomarker for cancer, QSOX1-L. A third patent allowance was received for a point-of-care apparatus and methods for detecting cancer that uniquely uses electrochemical or impedance spectroscopy (EIS). These allowances have increased the depth of AXIM’S IP portfolio to include 13 patent applications, including the above allowed applications, that cover AXIM’s innovative platforms and technologies. The Company see’s significant value in its IP portfolio whereas it may look to either further develop the covered technologies or license the IP to larger healthcare organizations, both creating significant upside value of the organization. “These allowances further validate both the novelty and underlaying science of our diagnostic technologies,” said John Huemoeller II, CEO of AXIM Biotechnologies. “While we continue to manufacture and ship our FDA-cleared diagnostic assays to customers through our commercialization partner, we have simultaneously continued to expand our value proposition through innovations in diagnostics field, that are now protected under the USPTO. We see our growing IP portfolio as a major opportunity for the organization, with an unrealized market value which probably exceeds the company’s current market capitalization. For instance, while the original SAR COVID-19 virus which plagued the world in recent years received extensive attention from the medical community, our now protected assay methodology can be applied to any future mutations or new SARS viruses or vaccines.” Below is an overview of AXIM’s patent portfolio: SARS-Cov-2. Neutralizing Antibody Testing and Treatment. 1 Allowed Patent; 3 Utility Patent Applications. The invention is a diagnostic test intended for semi-quantitative measurement of neutralizing antibodies in plasma, serum or whole blood of persons who have had recent or prior infection with SARS-CoV2 or have received a COVID-19 vaccine. DRY EYE DISEASE 1. Tests for Human Monomeric Lacritin. 1 Utility Patent Application The invention relates to a Rapid Point of Care test for Human Monomeric Lacritin. Lacritin is a tear protein that, in its monomeric form, autonomously promotes tearing and ocular surface survival. Lower concentrations of Lacritin may diagnose several eye diseases, including Blepharitis, Sjögren’s syndrome, Dry Eye Disease and other inflammatory conditions. 2. Tear Sample Collectors Systems and Methods. 1 Utility Patent Application Tear fluid analysis contributes to the greater understanding of various ocular and systemic diseases and obtaining adequate samples for tear analysis requires effective collection methods. Most tear sample collectors on the market use capillary designs that are intimidating to the patient. The invention relates to a laminated and looped tear sample collector that is cost-effective, easy to use and soft and non-intimidating to the user and patient. 3. Use of Micromesh Materials in Diagnostic Devices. 1 Provisional Patent Application When small sample sizes (0.1-2 microliters) are used, such as tears, there is a need for the sample to be spread out over application area for a proper flow. The invention allows dispersion of a small sample volume into mesh cells over a wide area controllable by the mesh size. This enables homogeneous sample dispersion over the entire sample application area. CANCER DIAGNOSTICS Systems and Methods for Rapid Diagnostic for Various Cancers. 1 Allowed Patent Application QSOX1-L, a splice variant of QSOX1, has been identified as a novel biomarker of bladder cancer and possibly other cancers in serum. Proprietary antibodies have been generated that selectively detect only this variant and not others. QSOX1-L has been used to develop a rapid and cost-effective diagnostic test for bladder and possibly other urologic cancers from urine. PLATFORM TECHNOLOGY Molecules and Related Assays, Test Kits and Methods. 1 Utility Patent Application, 1 Provisional Patent Application. The invention relates to the use of various recombinant proteins, test kits, test kit components and methods for detecting and measuring “binding antibodies” (for example, non-neutralizing antibodies) as well as “functional antibodies” (for example, neutralizing) in a single test and at the same time. Such test kit and method can advantageously improve the diagnosis and therapy of various diseases. NEW DIAGNOSTIC TEST Fentanyl Diagnostic Test. 1 Provisional Patent Application Researches have reported that broadly neutralizing antibodies may prevent lethality from the fentanyl class of synthetic opioids. The University of Houston is developing a vaccine targeting the dangerous synthetic opioid fentanyl that could block its ability to enter the brain. The invention relates to a test that can measure neutralizing antibodies against fentanyl, either therapeutic or generated by anti-fentanyl vaccine. The test can be used to monitor the vaccine’s response and help decide when a booster is needed. NEW TECHNOLOGY Point of Care Apparatus and Methods for Detecting Cancer Using Electrochemical Impedance or Capacitance Spectroscopy 1 allowed patent. 1 Allowed Patent, 1 Utility Patent Application The presence of cancer biomarkers or other analytes can be detected in the bodily fluid using EIS or ECS in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using EIS or ECS in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized. About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit . Forward-Looking Statements The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2023, and other reports we the SEC, which are available at . Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.